BridgeBio Pharma, Inc. Increase (Decrease) in Inventories
BridgeBio Pharma, Inc. (BBIO) reported Increase (Decrease) in Inventories of $28.17 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInInventories · last filed 2026-08-10
- BridgeBio Pharma, Inc. increase (decrease) in inventories for the quarter ending 2026-06-30 was $21.11M, a 57.69% increase year-over-year.
- BridgeBio Pharma, Inc. increase (decrease) in inventories for the quarter ending 2026-03-31 was $7.05M, a 120.89% increase year-over-year.
- BridgeBio Pharma, Inc. increase (decrease) in inventories for the quarter ending 2025-12-31 was $1.95M.
- BridgeBio Pharma, Inc. increase (decrease) in inventories for the quarter ending 2025-09-30 was $6.77M.
- BridgeBio Pharma, Inc. increase (decrease) in inventories for fiscal 2025 was $25.31M.
- BridgeBio Pharma, Inc. increase (decrease) in inventories for fiscal 2024 was $0.00.
- BridgeBio Pharma, Inc. increase (decrease) in inventories for fiscal 2023 was $0.00.
| Period end | Increase (Decrease) in Inventories 3 month | Increase (Decrease) in Inventories 6 month | Increase (Decrease) in Inventories 9 month | Increase (Decrease) in Inventories 12 month |
|---|---|---|---|---|
| 2026-06-30 | $21.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $28.17M 10-Q · filed 2026-08-10 | $30.12M derived: sum of 3 quarters · filed 2026-08-10 | $36.89M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $7.05M 10-Q · filed 2026-05-07 | $9.00M derived: sum of 2 quarters · filed 2026-05-07 | $15.78M derived: sum of 3 quarters · filed 2026-05-07 | $29.17M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $1.95M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $8.72M derived: sum of 2 quarters · filed 2026-02-24 | $22.11M derived: sum of 3 quarters · filed 2026-08-10 | $25.31M 10-K · filed 2026-02-24 |
| 2025-09-30 | $6.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $20.16M derived: sum of 2 quarters · filed 2026-08-10 | $23.36M 10-Q · filed 2025-10-29 | $23.36M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $13.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $16.58M 10-Q · filed 2026-08-10 | $16.58M derived: sum of 3 quarters · filed 2026-08-10 | $16.58M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $3.19M 10-Q · filed 2026-05-07 | $3.19M derived: sum of 2 quarters · filed 2026-05-07 | $3.19M derived: sum of 3 quarters · filed 2026-05-07 | $3.19M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $0.00 derived: sum of 2 quarters · filed 2026-02-24 | $0.00 derived: sum of 3 quarters · filed 2026-02-24 | $0.00 10-K · filed 2026-02-24 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $0.00 derived: sum of 2 quarters · filed 2025-10-29 | $0.00 10-Q · filed 2025-10-29 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $0.00 10-Q · filed 2025-08-05 | ||
| 2024-03-31 | $0.00 10-Q · filed 2025-04-29 | |||
| 2023-12-31 | $0.00 10-K · filed 2026-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |